5-MeO-MiPT

From PsychonautWiki
Jump to: navigation, search
Summary sheet: 5-MeO-MiPT
5-MeO-MiPT
5-MeO-MiPT.svg
Chemical Nomenclature
Common names 5-MeO-MiPT, "Moxy"
Substitutive name 5-Methoxy-N-methyl-N-isopropyltryptamine
Systematic name N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.


Smoked
Dosage
Threshold Common Heavy
5 - 5 - 10 - 15 - 20 mg
Light Strong
Threshold 5 mg
Light 5 - 10 mg
Common 10 - 15 mg
Strong 15 - 20 mg
Heavy 20 mg +
Duration
Total 5 - 8 hours
Onset 20 - 60 minutes
Peak 1 - 2 hours
Offset 1 - 2 hours
After effects 1 - 3 hours
Oral
Dosage
Threshold Common Heavy
3 - 3 - 7 - 15 - 20 mg
Light Strong
Threshold 3 mg
Light 3 - 7 mg
Common 7 - 15 mg
Strong 15 - 20 mg
Heavy 20 mg +
Duration
Total 5 - 8 hours
Onset 20 - 40 minutes
Come up 30 - 60 minutes
Peak 2 - 3 hours
Offset 2 - 3 hours
After effects 2 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-MeO-MiPT or colloquially as Moxy) is a lesser-known psychedelic substance of the tryptamine class that produces psychedelic effects when administered. It is structurally related to tryptamines like MiPT, 4-HO-MiPT, and 5-MeO-DiPT.

5-MeO-MiPT has no history of human usage prior to the 1985 publication of its synthesis and pharmacology by Repke, Grotjahn & Shulgin.[citation needed]

Anecdotal reports characterize the effects of this compound as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. An unpleasant body load is also often reported at higher dosages.

Very little is known about the pharmacological properties, metabolism and toxicity of this substance, and it has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices if using this substance.

Chemistry

5-MeO-MiPT or 5-methoxy-N-methyl-N-isopropyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT). 5-MeO-MiPT is the N-substituted isopropyl homologue of 5-MeO-DMT.[1]

Pharmacology

Further information: Serotonergic psychedelic

5-MeO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist[2][3] and additional mechanisms of action such as the inhibition of MAO (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically.

Subjective effects

This substance can be taken via oral ingestion or it can be smoked. When ingested orally the experience puts more of an emphasis on visual effects but can be broken up into two stages; the first half of the experience feels stimulating and entactogenic whilst the second half feels more similar to a traditional tryptamine psychedelic. When smoked, the physically and cognitively stimulating effects become emphasized.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 5-MeO-MiPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-MiPT is a research chemical with very little history of human usage.

Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

5-MeO-MiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 5-MeO-MiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.

Dangerous interactions

There are no known deaths from 5-MeO-MiPT but, as a monoamine reuptake inhibitor (MRI)[4], injury could occur when excessive doses are taken or when it is taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.[5]

Legal status

  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[6]
  • China: The drug is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.[7]
  • Finland: 5-MeO-MiPT was banned in Finland in December 2014.[8]
  • Japan: 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.
  • Latvia: 5-MeO-MiPT is a Schedule I drug.[9]
  • New Zealand: 5-MeO-MiPT is an analogue of DMT, so is a Class C controlled drug in New Zealand.[10]
  • Romania: 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.
  • United Kingdom: 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT[11], which is a Class A drug as a result of the tryptamine catch-all clause.[12]
  • United States: 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]
    • Florida: 5-MeO-MiPT is a Schedule I drug in Florida.[13]
    • Louisiana: 5-MeO-MiPT is a Schedule I drug (as of June 2013).[14]
    • Minnesota: Minnesota banned a series of drugs including 5-MeO-MiPT.[15]

See also

External links

Community

References

  1. http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=40
  2. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811
  3. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents | http://pubs.acs.org/doi/abs/10.1021/jm00145a007
  4. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17223101
  5. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
  6. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  7. Erowid China Psychoactive Law Update: September 2015 | https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf
  8. Finland's Prohibited Psychoactive Substances: December 19, 2014. https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf
  9. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
  10. http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576
  11. Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
  12. Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
  13. The 2015 Florida Statutes - Title XLVI CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL | http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html
  14. 5-MeO-MiPT Legal Status by Erowid | https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml
  15. 2015 Minnesota Statutes | https://www.revisor.mn.gov/statutes/?id=152.02